Thrombospondin-4 deletion does not exacerbate muscular dystrophy in β-sarcoglycan-deficient and laminin α2 chain-deficient mice

Muscular dystrophy is a group of genetic disorders that lead to muscle wasting and loss of muscle function. Identifying genetic modifiers that alleviate symptoms or enhance the severity of a primary disease helps to understand mechanisms behind disease pathology and facilitates discovery of molecular targets for therapy. Several muscular dystrophies are caused by genetic defects in the components of the dystrophin-glycoprotein adhesion complex (DGC). Thrombospondin-4 overexpression has been shown to mitigate dystrophic disease in mouse models for Duchenne muscular dystrophy (dystrophin deficiency) and limb-girdle muscular dystrophy type 2F (LGMD2F, δ-sarcoglycan deficiency), while deletion of the thrombospondin-4 gene exacerbated the diseases. Hence, thrombospondin-4 has been considered a candidate molecule for therapy of muscular dystrophies involving the DGC. We have investigated whether thrombospondin-4 could act as a genetic modifier for other DGC-associated diseases: limb-girdle muscular dystrophy type 2E (LGMD2E, β-sarcoglycan deficiency) and laminin α2 chain-deficient muscular dystrophy (LAMA2-RD). Deletion of the thrombospondin-4 gene in mouse models for LGMD2E and LAMA2-RD, respectively, did not result in worsening of the dystrophic phenotype. Loss of thrombospondin-4 did not enhance sarcolemma damage and did not impair trafficking of transmembrane receptors integrin α7β1 and dystroglycan in double knockout muscles. Our results suggest that thrombospondin-4 might not be a relevant therapeutic target for all muscular dystrophies involving the DGC. This data also demonstrates that molecular pathology between very similar diseases like LGMD2E and 2F can differ significantly.

Thrombospondin-4 deletion does not exacerbate muscular dystrophy in β-sarcoglycan-deficient and laminin α2 chain-deficient mice Paula Zarén & Kinga I. Gawlik * Muscular dystrophy is a group of genetic disorders that lead to muscle wasting and loss of muscle function.Identifying genetic modifiers that alleviate symptoms or enhance the severity of a primary disease helps to understand mechanisms behind disease pathology and facilitates discovery of molecular targets for therapy.Several muscular dystrophies are caused by genetic defects in the components of the dystrophin-glycoprotein adhesion complex (DGC).Thrombospondin-4 overexpression has been shown to mitigate dystrophic disease in mouse models for Duchenne muscular dystrophy (dystrophin deficiency) and limb-girdle muscular dystrophy type 2F (LGMD2F, δ-sarcoglycan deficiency), while deletion of the thrombospondin-4 gene exacerbated the diseases.Hence, thrombospondin-4 has been considered a candidate molecule for therapy of muscular dystrophies involving the DGC.We have investigated whether thrombospondin-4 could act as a genetic modifier for other DGC-associated diseases: limb-girdle muscular dystrophy type 2E (LGMD2E, β-sarcoglycan deficiency) and laminin α2 chain-deficient muscular dystrophy (LAMA2-RD).Deletion of the thrombospondin-4 gene in mouse models for LGMD2E and LAMA2-RD, respectively, did not result in worsening of the dystrophic phenotype.Loss of thrombospondin-4 did not enhance sarcolemma damage and did not impair trafficking of transmembrane receptors integrin α7β1 and dystroglycan in double knockout muscles.Our results suggest that thrombospondin-4 might not be a relevant therapeutic target for all muscular dystrophies involving the DGC.This data also demonstrates that molecular pathology between very similar diseases like LGMD2E and 2F can differ significantly.
Muscular dystrophy is a heterogeneous group of degenerative inherited disorders that lead to muscle function failure.Progressive muscle wasting, often starting from a young age, results in compromised mobility, breathing difficulties and feeding complications 1 .To this end, mutations in more than 60 genes have been implicated to cause muscular dystrophy, giving rise to broad clinical spectra of the disease 2 .Although U.S. Food and Drug Administration has approved the first gene therapy for some patients with Duchenne muscular dystrophy 3 , currently there are no specific cures available to these severe and complex disorders.Development of therapy is hindered by the fact that most muscular dystrophy subtypes are rare diseases 2 .
The connection between the cytoskeleton, transmembrane receptor complexes and the extracellular matrix is important for muscle homeostasis and function.This is underscored by the fact that some muscular dystrophy variants are caused by mutations in genes that are a part of attachment networks 4 .The dystrophin-glycoprotein complex (DGC) constitutes a major adhesion complex in skeletal muscle.It is composed of intracellular components dystrophin, syntrophins and α-dystrobrevin that link cytoskeleton with transmembrane proteins dystroglycan (α-and β), sarcoglycans (α-, β-, δ-, γ-and ζ) and sarcospan 4,5 .α-dystroglycan binds to several extracellular matrix ligands, including the laminin α2 subunit of the laminin-211 heterotrimer 6,7 .
Sarcoglycanopathies represent the most severe forms of LGMDs.They are rare autosomal recessive disorders and constitute about 10-25% of LGMDs worldwide 8 .][10] (prevalence of LGMD2E in Italian population is estimated at 0.86/1.000.000 11).Weakness of proximal muscles occurs in early childhood and eventually leads to loss of ambulation and variable range of respiratory insufficiency 8,9,[11][12][13] .Cardiac involvement is common in patients with LGMD2E 11 .
Severe form of LAMA2-RD, a congenital variant, is one of the most frequent among congenital muscular dystrophies (CMD), but prevalence variability in the different populations also needs to be considered.5][16] and 36% cases in China 17 .The majority of LAMA2-RD patients display severe phenotype 15 .Clinical manifestations are represented by neonatal onset of muscle weakness, delayed motor development, joint contractures, respiratory difficulties, and progressive weakness that prevents ambulation 15,[18][19][20][21] .The considerable frequency of subclinical cardiac involvement has been reported 15 .Premature death in early teens occurs in half of patients 22 .
Animal models for sarcoglycanopathies and LAMA2-RD exist, and they adequately mirror the disease course in humans.They have served as an important tool for understanding the disease mechanisms and test treatments 9,[23][24][25][26] .β-sarcoglycan-deficient mouse (Sgcb mouse), a model for LGMD2E, is characterized by loss of muscle force, cardiomyopathy, and elevated creatine kinase levels in plasma.The histopathological features of Sgcb muscle include extensive focal necrosis, inflammation, degeneration/regeneration cycles, variability of muscle fiber size, dystrophic calcifications, fibrosis and fatty infiltration [27][28][29] .
Dy 3K /dy 3K mouse model for LAMA2-RD displays complete deficiency of laminin α2 chain.Loss of laminin α2 chain results in the most severe phenotype among mouse models lacking proteins of cell adhesion complexes 30 .The mouse suffers from growth retardation, progressive muscle waste and dramatic weight loss, and survives up to 5 weeks of age 25,31 .Atrophy of muscle fibers, degeneration/regeneration cycles, apoptosis, inflammation, and fibrosis are among the hallmarks of the disease in dy 3K /dy 3K muscle 25,[31][32][33] .
Because the DGC provides critical structural support to muscle cell membrane, loss of any of its components leads to sarcolemma instability and rupture 4,[34][35][36] .Furthermore, loss of each DGC component results in destabilization of the entire complex 5,28,36,37 , which further aggravates sarcolemma fragility.Subsequent influx of calcium ions into muscle cell disrupts muscle homeostasis and ultimately leads to necrosis 38,39 .Cell death triggers inflammation and muscle repair, but muscle regeneration is either inefficient or eventually exhausted.As a result, muscle tissue is replaced by fibrotic lesions and fatty deposits.
Laminin α2 chain absence does not lead to drastic destabilization of the sarcolemma 34 .Molecular mechanisms involved in degeneration of laminin α2 chain-deficient muscle have not been entirely characterized.Loss of interaction between laminin α2 subunit and its receptors dystroglycan and integrin α7β1 leads to impaired signalling, which most likely results in increased protein degradation and decreased survival of muscle cells 4,33,40 .Additionally, impaired mitochondrial function and bioenergetic status could also contribute to muscle degeneration 41 .
Several studies in mouse models for the DGC-related muscular dystrophies have highlighted the role of genetic modifiers in modulation of disease phenotype [42][43][44][45] .Thrombospondin-4 (Thbs4) belongs to a family of glycoproteins involved in tissue remodelling upon injury 46,47 .In skeletal muscle it regulates the composition of the extracellular matrix, metabolism, and physiology; particularly in muscles with high content of oxidative fibers 48 .Overexpression of Thbs4 in dystrophin-deficient mdx mouse and δ-sarcoglycan-deficient Sgcd mouse mitigated dystrophic symptoms 43 .Consequently, deletion of the Thbs4 gene in these mouse models, exacerbated dystrophic phenotype 43 and enhanced cardiomyopathy 49 .The mechanism behind phenotype modulation by Thbs4 was attributed to enhancement of cellular trafficking of the adhesion complexes to stabilize sarcolemma and boost muscle integrity.Hence, it has been proposed that Thbs4 is an attractive therapeutic target for muscular dystrophies involving mutations in the DGC 43 .
Here we aimed at verifying whether Thbs4 could influence the phenotype of other muscular dystrophies associated with the DGC.For that purpose, we deleted the Thbs4 gene in β-sarcoglycan knockout mouse (Sgcb KO, the mouse model for LGMD2E), and in a mouse model for LAMA2-RD (laminin α2 chain-deficient dy 3K / dy 3K mouse).We found no exacerbation of the dystrophic phenotype in respective double knockout models (Sgcb/ Thbs4 and dy 3K /Thbs4).This indicates a non-protective role of Thbs4 in these two muscle disorders.Thbs4 was Figure 1.Deletion of thrombospondin-4 does not exacerbate outward signs of muscular dystrophy and does not worsen muscle function in mice with β-sarcoglycan deficiency.(a) Body weight analysis of 3-month-old wild-type (WT), Thbs4 KO, Sgcb KO, Sgcb/Thbs4 in males and females.There is a trend for increased weight in Sgcb KO females (p = 0.0697 WT vs Sgcb KO; p = 0.0002 Thbs KO vs Sgcb KO).Also, Sgcb/Thbs4 females are heavier than Thbs4 KO mice (p = 0.0279).Such differences were not noted in males.No significant difference in body weight were observed between Sgcb KO and Sgcb/Thbs4 neither in females (p = 0.1105) nor in males (p = 0.0883).(b) Open field test and stand-up test carried out on 3-month-old WT, Thbs4 KO, Sgcb KO and Sgcb/ Thbs4 mice.Sgcb KO and Sgcb/Thbs4 mice performed significantly poorer than WT mice in the open field test (p = 0.0020 and p = 0.0075, respectively) and in the stand-up test (p = 0.0214 and p = 0.0211, respectively), but no significant difference can be observed between Sgcb KO and Sgcb/Thbs4 mice in neither the open field test (p = 0.9947) nor the stand-up test (p = 0.9991).(c) Grip strength test performed in 2-month-old WT, Thbs4 KO, Sgcb KO and Sgcb/Thbs4 mice.Two-month-old dystrophic mice are weaker than control mice (p = 0.0043, Sgcb KO vs WT; p = 0.0.134,Sgcb KO vs Thbs4 KO; p = 0.0208, Sgcb/Thbs4 vs Thbs4 KO).There are no significant differences between Sgcb KO and Sgcb/Thbs4 mice.(d) Treadmill test of 2-month-old WT, Thbs4 KO, Sgcb KO and Sgcb/Thbs4 mice.Sgcb KO and Sgcb/Thbs4 mice performed significantly poorer than healthy mice (p < 0.0001), but no significant difference was observed between Sgcb KO and Sgcb/Thbs4 mice (p = 0.9989).All statistical analyses were performed using one-way ANOVA followed by Tukey's multiple comparison test.

Deletion of Thbs4 does not exacerbate muscle function in mice with β-sarcoglycan deficiency
To assess how Thbs4 deletion would affect the general phenotype of β-sarcoglycan-deficient mice, we analyzed body weight and physical performance of single knockout mice (Sgcb KO) and double knockout mice (Sgcb/ Thbs4) as well as control groups (wild-type (WT) and Thbs4 KO).Sgcb KO mice show outwards signs of muscular dystrophy manifested with muscle hypertrophy and increased body weight at approximately two months of age 27 .
Vol:.( 1234567890) www.nature.com/scientificreports/ We only observed mildly increased weight in Sgcb KO females at three months of age (Fig. 1a).Importantly, significant differences between Sgcb KO and Sgcb/Thbs4 (in both males and females) were not observed at this age (Fig. 1a).
To assess how Thbs4 deletion affects muscle strength and physical capacity in mice with β-sarcoglycan deficiency, Sgcb KO, Sgcb/Thbs4, WT and Thbs4 KO mice were subjected to open field activity test, stand-up test, grip strength test and treadmill training.The open field test and the stand-up test at 3 months of age showed differences between the control groups (WT, Thbs4 KO) and the dystrophic groups (Sgcb KO and Sgcb/Thbs4): dystrophic mice performed significantly poorer than healthy mice, but there was no difference between Sgcb KO and double knockout animals (Fig. 1b).The grip strength test at 2 months of age revealed a similar trend: dystrophic mice were weaker than controls, but muscle strength of Sgcb/Thbs4 mice was not decreased compared to Sgcb KO mice (Fig. 1c).
It has previously been shown that δ-sarcoglycan-deficient mice (Sgcd) lacking Thbs4 display reduced physical capacity compared to single-knockout Sgcd mice when subjected to forced treadmill running 43 .To assess if this also applies in β-sarcoglycan-deficiency, we subjected 2-month-old mice to treadmill running.Dystrophic mice performed significantly poorer than their age-matched healthy controls, as neither Sgcb KO nor Sgcb/Thbs4 mice were able to run for more than a few minutes (Fig. 1d).There was no difference in running time between Sgcb KO and Sgcb/Thbs4 (Fig. 1d).These results suggest that outward phenotype and muscle function in Sgcb KO and Sgcb/Thbs4 are equally affected.

Sarcolemmal stability is not impaired with Thbs4 deletion in β-sarcoglycan-deficient mice
It has previously been shown that Sgcd mice lacking Thbs4 exhibited greater sarcolemmal damage in myofibers after physical exercise, indicating that loss of Thbs4 in these muscles decreases sarcolemma stability 43 .Because neither Sgcb KO nor Sgcb/Thbs4 were able to run on treadmill, we could not compare the excess of sarcolemma rupture after training.However, even untrained Sgcb KO mice display substantial muscle cell membrane tearing 28,29 .Thbs4 deletion did not result in increased sarcolemma damage in untrained double knockout mice compared with Sgcb mice: we did not observe a greater uptake of Evans blue dye (EBD) in quadriceps, tibialis anterior, and triceps or muscles of double knockout mice (Fig. 2a).Quantification of EBD-positive cells in quadriceps muscle confirmed these observations (Fig. 2b), indicating that Thbs4 absence does not influence sarcolemmal stability in β-sarcoglycan-deficient muscle.

Deletion of Thbs4 does not exacerbate pathohistological features of muscular dystrophy in β-sarcoglycan-deficient muscles
Skeletal muscles of Sgcb KO mice already at young age show dystrophic morphological changes: central nucleation, fatty infiltration, necrosis and calcification 27,28 .Also, fibrosis is a feature of Sgcb-null muscle, which is especially pronounced in aged muscles 28,29 .To evaluate whether Thbs4 deletion worsens dystrophic features in Sgcb KO muscle, we performed hematoxylin and eosin staining of different muscles (quadriceps, tibialis anterior, triceps and diaphragm) isolated from 3-month-old WT, Thbs4 KO, Sgcb KO, and Sgcb/Thbs4 mice.Thbs4 KO muscle did not exhibit any signs of muscular dystrophy in the examined muscles (Fig. 3 and Supplemental Fig. S1).
A distinct increase of central nucleation, number of necrotic cells, fat cell infiltration, and calcification was seen in Sgcb KO and in double knockout muscle compared to healthy controls (Fig. 3 and Supplemental Fig. S1).Both Sgcb KO and Sgcb/Thbs4 muscles were severely affected by morphological dystrophic changes, but no differences regarding the dystrophic features were observed between these two groups (Fig. 3 and Supplemental Fig. S1).
This was confirmed by analysis of necrosis and inflammation.Sgcb and double knockout muscles (quadriceps and tibialis anterior) displayed large areas occupied with necrotic and inflammatory cells, as demonstrated by staining against mouse IgG [50][51][52] (Fig. 4a).Quantification of necrosis and inflammation showed large variation between dystrophic animals from the same group, but in general no significant difference between single knockout and double knockout animals was demonstrated (Fig. 4b).It has previously been shown that deletion of Thbs4 drastically increased fibrotic build-up in δ-sarcoglycan-deficient skeletal muscles 43 .Collagen III immunostaining demonstrated onset of fibrosis in 3-month-old Sgcb and Sgcb/Thbs4 muscles and visualized equal presentation of fibrotic material in both groups (Supplementary Fig. S2).
Heart muscle in Sgcb mouse shows pronounced necrosis and fibrosis from 5 months of age 28 .In 3-month-old Sgcb KO mice no cardiomyopathic changes could be detected (Supplementary Fig. S1), which stays in agreement with previous studies, where Sgcb hearts were reported to develop only mild cardiac abnormalities at young age 28 .No pathological changes were found in 3-month-old Sgcb/Thbs4 heart muscle (Supplementary Fig. S1).This indicates that absence of Thbs4 does not cause acceleration of cardiomyopathy in Sgcb KO mice.

Muscular dystrophy does not worsen with age in β-sarcoglycan double knockouts compared to β-sarcoglycan single knockouts
It has previously been shown that at one year of age, Thbs4 KO mice exhibit increased histopathological signs of muscular dystrophy, as well as reduced physical capacity 43 .Hence, it has been interpreted that loss of Thbs4 predisposes to muscular dystrophy.We examined older mice to explore whether β-sarcoglycan-deficient mice lacking Thbs4 would exhibit worsening of muscular dystrophy with age compared to Sgcb KO mice.Hematoxylin and eosin staining of quadriceps, tibialis anterior, and triceps muscles from 15-month-old WT, Thbs4 KO, Sgcb KO and Sgcb/Thbs4 mice was performed.Surprisingly, we did not find clear morphological signs of muscular dystrophy in Thbs4 KO muscles (Fig. 5).Moreover, we did not observe a difference between Sgcb KO and Sgcb/ Thbs4 mice regarding histopathological signs of muscular dystrophy (Fig. 5).Both β-sarcoglycan-deficient muscle and double knockout muscle exhibited massive infiltration of fatty tissue (Fig. 5).This was also confirmed by Oil Red O staining that visualizes fat (Supplementary Fig. S3).We did not detect a difference in the range of fatty infiltrates between Sgcb KO and Sgcb/Thbs4 muscle.
Apart from fat deposits, pronounced fibrosis is a feature of aged Sgcb muscle 28,29 .To explore whether loss of Thbs4 affects severity of fibrosis in β-sarcoglycan-deficient muscles, we analyzed fibrotic lesions in quadriceps, tibialis anterior and triceps isolated from 15-month-old mice (Fig. 6).As demonstrated by immunostaining with a fibronectin antibody, equally extensive fibrotic lesions were a feature of Sgcb and Sgcb/Thbs4 muscles (Fig. 6).
A particularly significant role was attributed to Thbs4 in protection of cardiomyocytes upon stress response.Consequently, ablation of the Thbs4 gene enhanced cardiomyocyte membrane instability in mdx mice 49 .Absence of Thbs4 did not affect heart muscle in 3-month-old Sgcb animals, but major pathogenic features (necrosis and fibrosis) become evident at 5 months of age in Sgcb cardiac muscle 28 .Hence, it was highly relevant to carry out analysis of heart phenotype at later stages of the disease in Sgcb/Thbs4 mouse.Thbs4 deletion did not cause any worsening of heart abnormalities in double knockout mice at 6 months and 15 months of age.Both Sgcb and Sgcb/Thbs4 hearts displayed the same degree of necrotic lesions at 6 months and fibrotic lesions at 15 months of age (Fig. 7).In summary, not a single dystrophic feature was aggravated by deletion of Thbs4 in Sgcb mice at any stage of the disease, suggesting minor involvement of the molecule in regulation of the pathophysiology in LGMD2E.This contrasts sharply with robust role of Thbs4 in modulation of the phenotype in Sgcd mice and mdx mice 43,49 .

Deletion of Thbs4 does not exacerbate muscular dystrophy in laminin α2 chain-deficient mice
Dy 3K /dy 3K mice display outward hallmarks of muscular dystrophy at 5 weeks of age such as emaciation, decreased body size, muscle wasting and weight loss 32 (Figs.8a, b).Deletion of Thbs4 did not worsen the outward phenotype of dy 3K /dy 3K mice: no significant differences in survival, overall size, muscle wasting, and body weight could be observed between dy 3K /dy 3K and dy 3K /Thbs4 double knockout mice (Fig. 8a, b).Because both dy 3K /dy 3K and dy 3K / Thbs4 animals were very sick, we could not perform any activity test.
Laminin α2-deficient muscle displays dystrophic features such as muscle fiber atrophy, centrally located nuclei, fibrosis and infiltration of inflammatory cells 25 .Both dy 3K /dy 3K and dy 3K /Thbs4 muscle showed those dystrophic features (Fig. 8c).However, no difference in degree of dystrophic changes was observed between dy 3K /dy 3K and dy 3K /Thbs4 muscle (Fig. 8c).Acute inflammatory response in the form of macrophage infiltration is a common characteristic of the laminin α2-deficient dystrophic muscle at the early stage of the disease 31 .Here, we investigated whether the deletion of Thbs4 would exacerbate inflammatory response in dy 3K /dy 3K muscle.Staining for CD68 (macrophages/monocytes) was performed in triceps and quadriceps of WT, Thbs4 KO, dy 3K /dy 3K and dy 3K / Thbs4.We found an increase of inflammatory cell infiltration between control muscles and dystrophic muscles (Fig. 8d), but no changes in the amount of macrophage/monocyte infiltrates in dy 3K /Thbs4 muscle compared to dy 3K /dy 3K were evident (Fig. 8d).
To investigate whether deletion of Thbs4 in laminin α2 chain-deficient muscles leads to an increase of fibrosis, muscles from WT, Thbs4 KO, dy 3K /dy 3K and dy 3K /Thbs4 mice were stained with a collagen III antibody (Fig. 8e).Immunostaining showed increased collagen content in dystrophic muscles (dy 3K /dy 3K and dy 3K /Thbs4) compared with control muscles (WT, Thbs4 KO).In healthy muscles collagen III is limited to perimysium, while dystrophic muscles display thickened deposits of collagen III in perimysium and increased collagen III expression in endomysium (Fig. 8e).We detected no difference in amounts of fibrotic lesions between dy 3K /dy 3K and dy 3K / Thbs4 mice (Fig. 8e).

Thbs4 is present merely in the extracellular compartment in muscles of laminin α2 chain-deficient and β-sarcoglycan-deficient mice
It has previously been demonstrated that Thbs4 is upregulated in δ-sarcoglycan-deficient and dystrophin-deficient muscle 43 .Microarray and proteomic analyses have shown an upregulation of Thbs4 in laminin α2-deficient muscle 53,54 .We performed qPCR to analyze Thbs4 transcripts in dy 3K /dy 3K and Sgcb muscles.A trend for upregulation of Tbhs4 mRNA in both dystrophic groups was observed (Supplementary Fig. S5).An immunofluorescence staining with antibody against Thbs4 was performed to determine protein expression and localization in Sgcb and dy 3K /dy 3K muscle.Thbs4 was expressed at very low levels in WT muscle, but it was present in neuromuscular junctions 55 (Fig. 9a, arrowheads).As expected, Thbs4 was not expressed in Thbs4 KO (data not shown), Sgcb/ Thbs4, or dy 3K /Thbs4 muscles (Fig. 9a).In agreement with previous findings, we detected extensive upregulation of Thbs4 in dy 3K /dy 3K muscle (Fig. 9a).Strongly increased production of Thbs4 was also found in Sgcb KO muscle (Fig. 9a).Thbs4 was expressed at high levels especially at dystrophic areas (Fig. 9a, white arrows).This indicates that Thbs4 is secreted in connection with inflammation, muscle remodeling and regeneration 56 .High magnification images indicated no clear intracellular deposits of Thbs4 (Fig. 9a).
Further, we analyzed in detail the localization of Thbs4 staining.It has been shown before that Thbs4 is located intracellularly in muscles of δ-sarcoglycan-deficient mice, from where it induces an ER (endoplasmic reticulum) stress response, which promotes trafficking of stabilizing protein complexes to the sarcolemma 43 .To investigate whether Thbs4 is located in the sarcoplasmic reticulum (SR) in Sgcb KO and dy 3K /dy 3K muscle, we performed a double immunofluorescence staining of Thbs4 and calsequestrin, as well as Thbs4 and calreticulin (Fig. 9b).Calreticulin is expressed in the ER, including the SR, whereas calsequestrin is SR-specific.We have not detected a clear signal for Thbs4 in the SR (Fig. 9b).
Extensive production and deposition of extracellular matrix proteins is a hallmark of muscular dystrophies.We stained for fibronectin, a glycoprotein expressed in the extracellular space upon tissue remodeling and in fibrotic lesions.Combined staining of Thbs4 and fibronectin indicated an extracellular localization of Thbs4, both in dy 3K /dy 3K and Sgcb KO muscle (Fig. 9c).Together, these results point towards Thbs4 role in tissue remodeling and its contribution to increased pool of extracellular proteins.This further indicates that Thbs4 might not be involved in sarcolemma-stabilizing mechanisms and increased protein trafficking in Sgcb and dy 3K /dy 3K muscle, as these mechanisms seem to require substantial levels of Thbs4 in the SR. 43,49,56.

Sarcolemmal protein complexes are not reduced in laminin α2-deficient or β-sarcoglycan-deficient mice with Thbs4 deletion
To further substantiate the results shown in Fig. 9, we investigated trafficking of adhesion complexes, we focused on expression of dystroglycans and integrins.As previously demonstrated, Thbs4 increases trafficking of stabilizing protein complexes to the sarcolemma in δ-sarcoglycan-deficient muscles, for example the DGC and integrins 43 .Conversely, deletion of Thbs4 in wild-type mice reduced sarcolemmal levels of integrin α7 and integrin β1 43 .
To assess how deletion of Thbs4 affects protein complexes stabilizing sarcolemma in β-sarcoglycan-deficient muscle, we performed an immunostaining for the integrins α7, β1 and dystroglycans in Sgcb KO, Sgcb/Thbs4, Thbs4 KO and WT muscle (quadriceps and tibialis anterior).Immunostaining showed an upregulation of integrin α7 in dystrophic muscles, with no apparent difference between Sgcb KO and Sgcb/Thbs4 muscle (quadriceps, Fig. 10 top row; tibialis anterior, Supplementary Fig. S4).Expression of integrin α7 was lost in necrotic muscle fibers (white arrows).We detected a similar expression pattern for integrin β1 (Fig. 10).It is noteworthy that living muscle cells expressed integrins at the cell surface even within necrotic areas (Fig. 10, white arrowheads for integrin α7 and inset for integrin β1).No difference in levels of integrin α7 or integrin β1 could be observed between WT and Thbs4 KO (Fig. 10).Immunofluorescence with antibodies against α-and β-dystroglycan showed no visible reduction of dystroglycans levels in Sgcb/Thbs4 muscle compared to Sgcb muscle (Fig. 10).These results indicate no disruption of protein trafficking to sarcolemma upon Thbs4 deletion.Immunostaining is not the optimal method to determine whether adhesion complexes are membrane anchored.It has been shown that sarcolemma-bound portion of α-dystroglycan is severely reduced in sarcoglycan deficiencies despite the positive immunofluorescence signal in the proximity of cell membrane 28 .It remains to be determined whether integrins are incorporated at the sarcolemma in Sgcb/Thbs4 muscles.However, the staining for both integrins and dystroglycans demonstrate clearly that the receptors were directed to the sarcolemmal compartment.In order to assess how deletion of Thbs4 affects sarcolemmal complexes inlaminin α2-deficiency, immunostaining for α-dystroglycan, β-dystroglycan and integrin α7β1 was performed in dy 3K /dy 3K , dy 3K /Thbs4, Thbs4 KO, and WT muscle.The expression pattern of integrin α7 and β1 was also similar in dy 3K /dy 3K and dy 3K /Thbs4 muscle: integrin α7 was severely reduced and integrin β1 was maintained in both mutants (Fig. 11).Signal for α-dystroglycan appeared stronger in muscles from both dystrophic groups.However, immunostaining did not indicate a downregulation of neither α-nor β-dystroglycan in dy 3K /Thbs4 muscle compared to dy 3K /dy 3K muscle (Fig. 11).This further suggests that Thbs4 does not have an intracellular role in promoting receptor trafficking to  the sarcolemma in laminin α2-deficient muscular dystrophy.In summary, even if there are subtle differences in the expression levels of adhesion receptors between single and double knockouts (Sgcb vs Sgcb/Thbs4 and dy 3K / dy 3K vs dy 3K /Thbs4), clearly, they do not make difference for the phenotype.

Discussion
Thrombospondin-4 has emerged to be a promising therapy target for both limb-girdle muscular dystrophy type 2F and Duchenne muscular dystrophy, as its overexpression mitigated dystrophic phenotype in mouse models of these muscular dystrophies.It was shown that the improved phenotype arose from increased stabilization of the sarcolemma by enhancing transport of sarcolemmal protein complexes in these two muscular dystrophies in mouse models 43 .It has therefore been proposed that Thbs4 could be a therapeutic agent for all muscular dystrophies involving adhesion complexes in the sarcolemma.
In this study, we aimed to verify whether Thbs4 is a universal target for DGC-related muscular dystrophies.We explored Thbs4 deletion in mouse models of β-sarcoglycan deficiency and laminin α2 chain deficiency.The deletion of the Thbs4 gene did not result in an exacerbation of muscular dystrophy in any of these two disorders, indicating that Thbs4 does not have the same disease-modifying effect as has been shown in mice models of Duchenne muscular dystrophy and LGMD2F.This was demonstrated by analysis of outward phenotype, muscle function, and pathohistological features at wide range of ages.
A possible explanation for the absence of disease-modifying effect of Thbs4 in Sgcb mice is that Thbs4 is merely located in the extracellular compartment in Sgcb muscle, and distinct intracellular portion of Thbs4 was not detected.This contrasts with Sgcd muscle, where Thbs4 is expressed intracellularly, inducing an ER stress response that increases trafficking of stabilizing protein complexes to the sarcolemma 43 .Consequently, the expression of adhesion complexes (integrin α7β1 and dystroglycans) was not further perturbed by deletion of Thbs4 in Sgcb muscle, as it was seen in Sgcd mice 43 .Moreover, the number of EBD-positive cells remained unaltered after Thbs4 deletion, thus indicating that Thbs4 does not affect membrane stability in muscles of Sgcb mice.Importantly, the extracellular deposits of Thbs4 were allocated to dystrophic/necrotic areas of muscle, which points out the role of Thbs4 in repair mechanism and tissue remodeling [57][58][59][60] .However, it is not excluded that Thbs4 presence in the extracellular milieu could also be a sign of generally increased production of extracellular matrix proteins that later contribute to fibrosis in muscle disease.In dystrophic muscle, representing a highly disorganized milieu, the remodeling function could turn into fibrotic process.For example, it has been demonstrated that thrombospondin-4 promotes TGF-β signaling and contributes to fibrosis in hypertrophic scar formation 61 .On the other hand, anti-fibrotic properties of Thbs4 have been described and deletion of Thbs4 has been shown to promote fibrosis and inflammation in heart and vessels 57,58 .Yet, we have not detected enhancement of these processes in Sgcb KO and dy 3K /dy 3K muscles lacking Thbs4.
The results described in this study are somewhat surprising because pathogenesis of β-sarcoglycan-deficient and δ-sarcoglycan-deficient muscular dystrophy is similar.Deficiency of either of these sarcoglycan subtypes leads to loss of the DGC and thus instable sarcolemma 28,[34][35][36][37]62 . It ould therefore be logical to assume that loss of Thbs4 in Sgcb mice would lead to an exacerbation of muscular dystrophy in the same way as was seen in Sgcd model.It is possible that deletion of Thbs4 affects β-sarcoglycan-deficient and δ-sarcoglycan-deficient muscles differently due to individual properties of these two proteins.It has previously been shown that each of the sarcoglyans has unique characteristics, for example specific binding sites, and might perform unique functions 12 .δ-sarcoglycan has been shown to interact directly with a H + -ATPase 63 and α-sarcoglycan acts as an ATPase 64,65 .Comprehensive roles and interactions of each of the sarcoglycans, including β-sarcoglycan, have not been fully understood.Hence, Thbs4 deletion in two different sarcoglycan knockout models could have diverse repercussions.
Finally, the precise roles of thrombospondins in different pathologies have not yet been clearly delineated.The thrombospondin family have been shown to scaffold cell-matrix and cell-cell interactions, regulate the molecular composition of the extracellular matrix in response to tissue injury and tissue healing [46][47][48]60,66,67 . Both proective and detrimental effects have been associated with expression of thrombospondins in various cell types and at specific stages after injury 43,46,49,57,58,68 .In this context, the role of thrombospondin-4 in pathogenesis of various diseases might be regulated in a very fine-tuned way due to subtle differences in molecular signature of pathologic milieu.
It is also worth mentioning that we did not observe any pathological changes in muscles from single knockout mice lacking Thbs4 even at age of 15 months.This finding is discrepant to data published by Vanhoutte et al., where Thbs4 knockout mice showed signs of mild muscular dystrophy at 6 months of age 43 .We have not investigated red skeletal muscle with high oxidative metabolism (soleus), in which decreased muscle mass has been observed 48 , but we have not detected strength deficit nor clear weight reduction in Thbs4 KO mice.Lack of Figure 8. Deletion of Thbs4 does not exacerbate pathohistological features of muscular dystrophy in laminin α2-deficient muscles.(a) Double knockout mice (dy 3K /Thbs4) present the same outward phenotype as single knockout (dy 3K /dy 3K ) animals; severe muscle wasting, and loss of muscle mass is evident.(b) Body weight analysis of WT, Thbs4 KO, dy 3K /dy 3K and dy 3K /Thbs4 mice.There is no significant difference in body weight between dy 3K /dy 3K and dy 3K /Thbs4 mice (p = 0.9998), but they weigh significantly less than control mice (p = 0.8401, one-way ANOVA followed by Tukey's multiple comparison test.(c) Hematoxylin and eosin staining of quadriceps and triceps muscles of 5-week-old WT, Thbs4 KO, dy 3K /dy 3K and dy 3K /Thbs4 mice.Dystrophic muscles (dy 3K /dy 3K and dy 3K /Thbs4) display histopathological signs of muscular dystrophy typical for laminin α2 chain deficiency: muscle fiber atrophy, centrally located nuclei, fibrosis, infiltration of inflammatory cells.No difference in degree of dystrophic changes was observed between dy 3K /dy 3K and dy 3K /Thbs4 muscle.(d) Immunofluorescence staining for CD68 (green) in quadriceps muscle of 5-week-old WT, Thbs4 KO, dy 3K /dy 3K and dy 3K /Thbs4 mice.CD68 depicts macrophage/monocyte infiltration.Higher magnification is shown in the bottom panel.Collagen IV (red) outlines the muscle fiber.DAPI (blue) visualizes nuclei.Dystrophic muscle (dy 3K /dy 3K and dy 3K /Thbs4) displays an increased number of macrophages/monocytes compared to healthy control muscles.No difference in the amount of macrophage/monocyte infiltrates was seen between dy 3K /dy 3K and dy 3K /Thbs4.(e) Immunofluorescence staining with collagen III in quadriceps muscle of 5-week-old WT, Thbs4 KO, dy 3K /dy 3K and dy 3K /Thbs4 mice.Increased collagen III content, which represents accumulation of fibrosis, was observed in dystrophic muscles compared to healthy muscles.No difference regarding amount of collagen III between dy 3K /dy 3K and dy 3K /Thbs4 was visible.Bars, 50 μm.◂ dystrophic phenotype in Thbs4 knockout mice could indicate why we did not observe worsening of dystrophic symptoms in Sgcb/Thbs4 animals.One must also mention that our study and the study by Vanhoutte et al. differ substantially in experimental design and experimental protocols.Additionally, Thbs4 KO mice were not backcrossed to Sgcb background.This could give rise to differences in results obtained.
Thbs4 is clearly upregulated in mice with laminin α2-deficiency, as has been demonstrated here and previously by others 53,54 .However, just as in Sgcb mice, Thbs4 was found only in the extracellular compartment in laminin α2-deficient muscle, and we did not observed exacerbation of muscular dystrophy by deletion of Thbs4.www.nature.com/scientificreports/This further supports our theory that Thbs4 does not have protective role in muscle when located extracellularly, at least in the two investigated mouse models.Membrane instability is not considered to be the main reason for cell degeneration and muscular dystrophy in laminin α2 deficiency.Instead, it is believed that lack of signaling between laminin α2 and transmembrane receptors integrin α7β1 and dystroglycan leads to myofiber degeneration 40 .Since the phenotype of double knockout was not worsened, it is safe to assume that signaling events in double knockout muscles were no further perturbed.In agreement with this, we did not detect a difference in expression of dystroglycan in double knockout mice compared to dy 3K /dy 3K mice.This confirms that Thbs4 does not have an obvious intracellular role in laminin α2-deficiency.It is also noteworthy that the expression pattern of Thbs4 in β-sarcoglycan deficiency and laminin α2 chain deficiency is comparable even though they do not share all pathological mechanisms and clinical manifestations.In contrast, it remains to be clarified why this expression pattern differs so much between the two much more similar diseases: LGMD2E and 2F.Taken together, our findings suggest that Thbs4 might not have the same disease-protective effect in mouse models of LGMD2E and LAMA2-RD as it was shown to have in mouse models of Duchenne muscular dystrophy and LGMD2F.We suggest that the differences stem from the fact that Thbs4 is present only in the extracellular space in muscles of Sgcb and dy 3K /dy 3K mice, and consequently does not induce intracellular trafficking of protein complexes to stabilize the sarcolemma.We cannot exclude that overexpression of Thbs4 in Sgcb and dy 3K /dy 3K mice by transgenic means and strong expression of Thbs4 in the sarcoplasmic reticulum could result in improvement of the phenotype.On the other hand, it could also contribute to an additional increase of extracellular matrix content around muscle fibers that is detrimental for muscle function.In any case, lack of this evidence is clearly a limitation of our study.Nevertheless, we suggest that Thbs4 might not necessarily be a universal therapeutic target for muscular dystrophies involving the DGC.These findings point out the importance of verification of promising therapeutic approaches, even though it would be logically justified to assume that the same therapeutic strategy would be effective in diseases with similar pathogenesis.Our study also demonstrates how vastly complicated muscular disorders are, when one protein plays different roles in two closely related disorders as LGMD2F and LGMD2E.Consequently, molecular pathology of similar diseases could be surprisingly unique and should be thoroughly compared.

Ethics statement
All animal experiments were approved by the Malmö/Lund (Sweden) Ethical Committee for Animal Research (ethical permit numbers M152-14 and M173-19), in accordance with guidelines from the Swedish Board of Agriculture.All experiments were performed in accordance with laws and regulations issued by the Swedish Board of Agriculture.Experiments involving live animals were reported according to the ARRIVE guideline.

Immunohistochemistry
Cryosections were fixed in ice-cold acetone for 8 min at −20 °C and then washed in PBS.For α-dystroglycan staining sections were fixed in 8% formaldehyde and ice-cold methanol.Sections were blocked in 3% BSA-PBS for 20 min and incubated for 90 min at room temperature with following primary antibodies diluted in blocking buffer: anti-Thbs4

Functional tests
Sgcb/Thbs4, Sgcb KO, Thbs4 KO and wild-type mice were subjected to functional tests at 2 months and 3 months of age.Open field activity test: mice were transferred to a new cage for 5 minutes.Time spent on active exploration of the cage was measured.Stand up test: during the open field activity test, the number of times that the animal was rising to a standing position on hind legs were noted.Grip strength test: the grip strength was measured by letting animals pull a metal bar with their forelimbs on a grip strength meter (Columbus Instruments).Animals were subjected to the experiment five times, of which the three highest scores were considered, and the mean value was calculated.Body weight was recorded in parallel.Results are presented as normalized strength (force (g)/body weight (g)).Forced treadmill running: two-month-old Sgcb/Thbs4, Sgcb KO, Thbs4 KO and wild-type mice were exercised on a treadmill Exer 6 M (Columbus Instruments) at a downhill angle of 15°.
Mice were exercised at a speed of 6 m/min for 2 min and then increasing the speed to 13 m/min until fatigue or for a maximum of 30 min.

Evans blue dye uptake
To assess sarcolemmal capacity of skeletal muscle cells, mice were injected intraperitoneally with Evans blue dye (EBD) dissolved in sterile saline (concentration: 0.5 mg EBD/0.05 ml saline; amount injected: 50 µL/10 g body weight).After 24 h, animals were sacrificed, and muscles were collected and frozen in liquid nitrogen.Muscle cryosections were stained with laminin antibody to visualize EBD-positive and EBD-negative muscle fibers.Pictures covering the whole muscle were taken in fluorescent microscope (10× magnification) and subsequently stitched in Photoshop (version 10.0.19041.3636,https:// adobe.com).The percentage of EBD-positive fibers was then calculated using ImageJ software (version 1.53e, https:// imagej.net/ ij/) with cell counter plug-in.

Necrosis quantification
Muscle cryosections (quadriceps femoris and tibialis anterior) from 3-month-old mice were stained with antimouse IgG conjugated with 546 fluorochrome.Pictures covering the whole muscle were taken (10× magnification) and stitched in Photoshop (version 10.0.19041.3636,https:// adobe.com).In order to avoid false-positive signal for quantification, artefacts, non-muscle tissue and background staining were manually removed from images using Photoshop (version 10.0.19041.3636,adobe.com).No other modifications were applied to images.The area corresponding to IgG labelling was quantified in relation to the entire area of muscle cross-section using ImageJ software (version 1.53e, https:// imagej.net/ ij/).

mRNA analysis
RNA was isolated from 2-month-old wild-type, Sgcb and Thbs4 KO quadriceps muscle and from 5-week-old dy 3K /dy 3K quadriceps muscle using Qiagen RNeasy Plus Universal Kit (Qiagen) according to manufacturer's specification.Briefly: muscles were incubated in Qiazol lysis reagent and homogenized in TissueLyser (Qiagen).
Genomic DNA Eliminator Solution was added, followed by chloroform.Samples were centrifuged at 4 °C in order to separate RNA from other cellular components.The aqueous phase containing RNA was transferred to RNA binding columns and washed in several steps.RNA was eluted with RNase free water by brief centrifugation.RNA concentration was determined using Nanodrop (Thermofisher).The quality of RNA samples was assessed using Agilent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit).Five hundred nanograms of muscle RNA were used to synthesize cDNA with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to manufacturer's protocol.Briefly, 10 μL RNA was transferred to a master mix containing 3.2 μL nuclease-free water, 2.0 μL 10X RT buffer, 0.8 μL 25 dNTP Mix, 2.0 μL RT random primers, 1.0 μL MultiScribe Reverse Transcriptase, 1.0 μL RNase inhibitor.Samples were placed in a thermal cycler for cDNA reverse transcription (25 °C for 10 min, 37 °C for 120 min, 85 °C for 5 min, 4 °C).
Five nanograms of cDNA was used for qPCR, together with Taqman Fast Advanced Master Mix (Applied Biosystems) and TaqMan probes detecting mouse thrombospondin-4 and β-actin (reference gene) (Assay ID: Mm00449057_m1 and Mm04394036_g1, respectively; Applied Biosystems).Each probe spanned two exons of the respective gene.The amplification was performed in a One-Step Real-Time PCR System (Applied Biosystems), including no-RT treated RNA samples as control reactions.Comparative C T method was used for relative quantitation.

Statistical analysis
All statistical analyses were performed with Graph-Pad Prism software (version 8, https:// www.graph pad.com/).Averaged data were reported as mean ± SD.The number of samples is indicated on the graphs.For assessing differences between two groups student's t-test was applied.One-way ANOVA followed by Tukey's multiple comparison post-hoc test was used when comparing more than two groups.Statistical significance was accepted for p < 0.05.

Figure 3 .
Figure 3. Deletion of Thbs4 does not exacerbate pathohistological features of muscular dystrophy in β-sarcoglycan-deficient muscles.Hematoxylin and eosin staining of quadriceps and tibialis anterior isolated from 3-month-old WT, Thbs4 KO, Sgcb KO and Sgcb/Thbs4 mice.Thbs4 KO muscle does not exhibit histopathological signs of muscular dystrophy.Dystrophic mice (Sgcb KO and Sgcb/Thbs4) show histopathological signs of muscular dystrophy: necrotic cells (black arrows), inflammation (light blue arrows), regeneration (fibers with centrally located nuclei), calcification (green arrows), fatty tissue deposits (dark blue arrows).No difference regarding the degree of dystrophic changes was seen between Sgcb KO and Sgcb/Thbs4 muscle.At least five mice from each group were analyzed.Bar: 50 μm.

Figure 4 .
Figure 4. Deletion of Thbs4 does not increase necrosis and inflammation in Sgcb muscle.(a) Immunostaining with mouse IgG antibody (red) shows necrotic lesions/inflammatory sites in quadriceps and tibialis anterior muscles from 3-month-old dystrophic animals.No such lesions were detected in Thbs4 KO muscle.Staining for collagen IV (in green) delineates muscle fibers.Bar: 50 μm.(b) Quantification of necrotic areas in quadriceps and tibialis anterior of Sgcb and Sgcb/Thbs4 mice shows no significant difference between groups for both muscles (p = 0.6563 and p = 0.9285, student's t-test).

Figure 5 .
Figure 5. Deletion of Thbs4 does not enhance muscular dystrophy in aged Sgcb muscle.Hematoxylin and eosin staining of quadriceps femoris, tibialis anterior and triceps brachii isolated from 15-month-old WT, Thbs4 KO, Sgcb KO and Sgcb/Thbs4 mice.Thbs4 KO muscle does not exhibit histopathological signs of muscular dystrophy.Sgcb KO and Sgcb/Thbs4 muscles display equally pronounced fatty infiltrates (dark blue arrows) and fibrosis (yellow arrows).At least three mice from each group were analyzed.Bar, 50 μm.

Figure 6 .
Figure 6.Fibrosis is not enhanced in Sgcb/Thbs4 aged muscle.Immunostaining with an antibody against fibronectin shows equally strong expression in quadriceps femoris, tibialis anterior and triceps brachii isolated from 15-month-old Sgcb KO and Sgcb/Thbs4 mice.At least four mice from each group were analyzed.Bar, 75 μm.

Figure 7 .
Figure 7. Deletion of Thbs4 does not aggravate cardiomyopathy in Sgcb mouse.Hematoxylin and eosin staining of heart muscle isolated from 6-month-old and 15-month-old WT, Thbs4 KO, Sgcb KO and Sgcb/Thbs4 mice.The same degree of focal necrosis (6-month-old mice) and fibrosis (15-month-old mice) was observed in Sgcb KO and Sgcb/Thbs4 mice.Two mice from each group were analyzed.Bar, 50 μm.

Figure 9 .
Figure 9. Thbs4 is upregulated merely in the extracellular compartment in laminin α2 chain-deficient and β-sarcoglycan-deficient muscles.(a) Immunofluorescence staining for Thbs4 (green) in quadriceps muscle of 3-month-old WT, dy 3K /dy 3K , Sgcb KO, dy 3K /Thbs4 and Sgcb/Thbs4 mice at low and high magnification.To simplify the figure, Thbs4 KO muscle was omitted, Thbs4 deletion is represented by respective double knockout muscles.Thbs4 is expressed at low levels in WT muscle, but strongly expressed in the neuromuscular junction (white arrowhead, also in panel b).As expected, Thbs4 is not expressed in Sgcb/Thbs4 and dy 3K /Thbs4 muscle.An upregulation of Thbs4 was evident in dy 3K /dy 3K muscle and Sgcb KO muscle.White arrows indicate high Thbs4 expression at the dystrophic areas in Sgcb KO muscle.High magnification of Thbs4 staining presents extensive deposits of the protein around the cells, but not intracellularly.(b) Double immunofluorescence staining for Thbs4 (green) and calsequestrin (red) (top panel) and Thbs4 (green) and calreticulin (red) (bottom panel).Thbs4 is absent from sarcoplasmic reticulum in dy 3K /dy 3K and Sgcb KO muscles.(c) Double immunofluorescence staining of Thbs4 (green) and fibronectin (red).Thbs4 colocalizes with fibronectin in the extracellular compartment in dy 3K /dy 3K and Sgcb KO muscles.At least three mice from each group were analyzed.Bars, 75 μm.

Figure 10 .
Figure 10.Expression pattern of sarcolemmal receptor complexes is similar in Sgcb and Sgcb/Thbs4 muscle.Immunofluorescence staining for integrin α7, integrin β1, α-dystroglycan and β-dystroglycan in quadriceps muscle of WT, Thbs4 KO, Sgcb KO, and Sgcb/Thbs4 mice (2-3-month-old animals).Integrin α7 is upregulated in dystrophic groups compared to controls, but no difference can be seen between Sgcb KO and Sgcb/Thbs4 muscle.Loss of integrin expression has been observed at the sarcolemma in necrotic cells (white arrows), while it was maintained in living cells in dystrophic areas (white arrowheads).No reduction of integrin α7 is seen in Thbs4 KO muscle compared to WT muscle.The same staining pattern was detected for integrin β1.Insets show necrotic areas, where expression of integrin β1 was clearly preserved in living cells.Expression of α-and β-dystroglycan was preserved in Sgcb KO and Sgcb/Thbs4 mice.No visible change in expression between dystrophic and healthy groups was observed.
upregulated in dy 3K /dy3Kand Sgcb KO muscle, but only in the extracellular compartment and not intracellularly as described for other muscular dystrophy mouse models.Hence, the molecule could contribute to fibrotic phenotype rather than directly supporting sarcolemma stability through increased intracellular trafficking mechanisms.
Vol.:(0123456789) Scientific Reports | (2024) 14:14757 | https://doi.org/10.1038/s41598-024-65473-8www.nature.com/scientificreports/muscle from WT, After washing with PBS, appropriate secondary antibodies (except for IgG staining) diluted 1:500 in PBS were applied for 1 h at room temperature, and then for 2 min with DAPI nuclear DNA stain with PBS washing before and after.Sections were mounted in Invitrogen PermaLong Diamond Antifade Mountant (Thermo Fisher Scientific) and analyzed using a Zeiss Axioplan 2 microscope.The images were captured using ORCA camera and Openlab software (version 4).The same exposure times were used when photographing the same staining in different mouse groups.